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Abstract
Background: The risk of coronary heart disease (CHD) is related to environmental factors and genetic variants.
Apolipoprotein E (apoE) polymorphisms are heritable determinants of total and low-density lipoprotein cholesterol,
with some authors suggesting an association between the ε4 allele and CHD. We investigated the relationship
between apoE genotype and age at referral to a specialized lipid clinic by the primary care physician and whether
the benefits of treatment with statin differed between genotypes.
Methods: We assessed individual apoE genotypes and lipid blood profile in a total of 463 patients followed at a
specialized lipid clinic due to dyslipidemia, with a 3-year median follow-up time. The primary care physician at the
time of the referral had no access to the apoE genotyping results. Carriers of apoE ε4/ε2 genotype were excluded.
Results: The frequencies of ε2, ε3 and ε4 alleles were 7.8, 78.9 and 13.3%, respectively. There were no significant
differences between genders. Although with similar lipid profiles and antidyslipidemic drug usage at baseline, ε4-
carriers were referred to the clinic at a younger age (44.2 ± 14.7 years) compared with non-ε4 carriers (50.6 ± 13.8
years) (p < 0.001), with a substantially younger age of referral for homozygous E4/4 and for all genotypes with at
least one copy of the ε4 allele (p < 0.001 for trend). Although both ε4 and non-ε4 carriers achieved significant
reductions in total cholesterol during follow-up (p < 0.001 vs. baseline), the mean relative decrease in total
cholesterol levels was higher in non-ε4 carriers (-19.9 ± 2.3%) compared with ε4 carriers (-11.8 ± 2.3%), p = 0.003.
Conclusion: Our findings support the concept that there is a reduced response to anti-dyslipidemic treatment in
ε4 carriers; this can be a contributing factor for the earlier referral of these patients to our specialized lipid clinic
and reinforces the usefulness of apoE genotyping in predicting patients response to lipid lowering therapies.
Background
Coronary heart disease (CHD) is the main cause of mor-
tality in developed countries. The risk of CHD may be
influenced by environmental factors and genetic muta-
tions in a number of genes controlling blood lipids and
other risk factors. One of the most studied genes is the
one coding for apolipoprotein E (apoE), located in chro-
mosome 9 [1]. ApoE is a serum glycoprotein that plays
a critical role in lipid metabolism [2]. It serves as a
ligand for cell-surface receptor uptake of chylomicrons
and very low-density lipoproteins (VLDL) on the liver
[3] and controls intestinal cholesterol absorption[4].
A common polymorphism in the APOE gene
(rs429358, rs7412) results in three isoforms called
apoE2, apoE3 and apoE4, which are coded by three
codominant alleles (designated as ε2, ε3a n dε4), giving
rise to six different genotypes [5]. The impact of apoE
on plasma lipids is well known and may be partly
related with increased CHD risk, with increasing plasma
total cholesterol (TC) and low density lipoprotein (LDL)
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However, the effect on HDL, apolipoprotein (apo) A or
lipoprotein (Lp) (a) is less clear[9].
The results of epidemiologic studies examining the
association between apoE genotypes and cardiovascular
outcomes are inconsistent. Earlier data pointed to a
clear gradient of risk conferred by the ε4 allele, with
ε4-carriers particularly prone to develop disseminated
coronary lesions, to be submitted to coronary revascu-
larization procedures and to die from CHD [10-13].
However, these results have been questioned by Ward et
al., that found no association between apoE genotypes
and CHD in a recent population study[14].
Based on this, the purpose of our investigation was
(1) to determine the apoE genotype distribution and its
association with plasma lipid traits in a population
referred to a specialized lipid outpatient clinic, (2) to
investigate whether the ε4 allele influences the age of
referral to the clinic, and if this was the case, (3) to
assess if patients with the ε4 allele were poorer respon-
ders to lipid-lowering therapeutic interventions.
Methods
Study design and participants
We conducted a retrospective observational study based
on the analysis of the clinical records of 691 patients
consecutively admitted and followed in a tertiary hospi-
tal specialized dyslipidemia outpatient clinic between
January 1994 and October 2007. All patients were
referred to consultation by their primary care physician
or by other specialist within the hospital due to mark-
edly abnormal, difficult to control lipid profile or due to
suspected familial dyslipidemia. All patients were fol-
lowed in either six-monthly or annual outpatient consul-
tations, as decided appropriate by the attending
physician, with regular assessment of laboratory and
clinical parameters. All patients were treated to target
the proposed LDL level recommended by the ATP III
guidelines[15], by the use of dietary and pharmacological
strategies. No formal recommendations were given
regarding which type of drugs should be used for reach-
ing the lipidic target. Apolipoprotein E genotypes were
not taken in account when making therapeutic decisions
regarding lipid-lowering drugs, as genotyping was per-
formed solely with an investigational purpose. We con-
ducted a 3-year follow-up analysis of blood lipids,
namely TC, LDL, HDL and triglycerides. The study was
approved by the local institutional board and all patients
gave informed consent.
Risk factors assessment
Baseline, demographic and clinical variables are
collected, including age at referral, gender, prior history
of CHD, diabetes mellitus, smoking status, alcohol
consumption, use of a salty diet and practice of exercise.
Diabetes was defined as fasting glucose ≥ 126 mg/dL or
use of hypoglycemic drugs and actual smoker if smoking
one or more cigarettes per day in the last year. Alcohol
consumption was positive in the patient consumed
more than two units of alcoholic beverages per day. Use
of a salty diet was considered if the patient added table
salt to food. Regular exercise was defined by the perfor-
mance of three or more periods of moderate exercise
per week. On the first consultation, several baseline
laboratory variables were obtained and a complete lipid
profile was assayed by standard techniques in 12-h fast-
ing blood samples, including TC, HDL, LDL, triglycer-
ides, apoA and apoB and Lp(a) levels. Peripheral blood
samples were obtained from each patient and dispatched
immediately to analysis in our hospital central labora-
tory at 4°C before processing.
DNA extraction and apoE genotyping
DNA was extracted from whole-blood specimens
according to standard procedures. Genomic DNA from
these samples was analyzed for apoE polymorphisms
(rs7412 and rs429358) using polymerase chain reaction
and reverse hybridization; apoE concentrations were
measured by nephelometry. Importantly, at the time of
referral, no referring physician was aware of the apoE
genotype of the patient, as these tests were only
requested after this first medical contact in the hospital.
Statistical analysis
Allele frequencies were determined using the gene
counting method. Hardy-Weinberg equilibrium for the
distribution of the genotype was performed. Continuous
variables were expressed as mean ± SD. Median and
interquartile range were used if the distribution was not
normal, assessed by the use of the Kolmogorov-Smirnov
test. The Student unpaired t-test for normal variables
and the Mann-Whitney U test for non-normal variables
were used for comparisons among groups. Paired-sam-
ples T-test was used for comparison between baseline
and follow-up assessments. Categorical variables were
presented as percentages, and were compared using c2
or Fisher’s exact test.
The number of patients in some individual genotype
groups was too small to support group comparisons;
therefore, and in a similar way to several other reports,
we next compared patients with one or more copies of
the ε4 allele (ε4-carriers) to those without (non-ε4c a r -
riers). As in many other studies of this nature, eight
subjects with the E4/2 genotype were excluded from the
subsequent analyses since they could not be simply clas-
sified into any single allele group[14], because of the
putative opposite effects of these two alleles in lipid
levels. Plasma Lp(a) and triglycerides values were
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to improve the normality of the distributions. All statis-
tical analyses were performed using SPSS 13.0 (Chicago,
Illinois) with the level of significance set at p < 0.05.
Results
Of the 691 patients who were studied in the outpatient
lipid consult, 228 were not genotyped, leaving a final
sample with complete data for 463 patients, all Cauca-
sian of Southern European ancestry. The observed dis-
tribution of apoE genotypes among patients, separately
by man and women, is presented in Table 1. The fre-
quencies of ε2, ε3a n dε4 alleles were 7.8, 78.9 and
13.3%, respectively. Overall, 112 of 463 patients (24.2%)
were carriers of the ε4 allele and 351 (75.8%) were non-
ε4 carriers. The distribution of the apoE alleles was not
in Hardy-Weinberg equilibrium. No significant differ-
ences were found among gender regarding the distribu-
tion of the alleles.
The apoE ε4-carriers and non-ε4 carriers groups were
compared regarding demographic, clinical and labora-
tory variables (Table 2 and 3). The studied population
had a small percentage of patients with prior CHD
(4.2%) but we found a significant proportion of diabetic
patients (24.9%). At baseline, no differences were found
among patients with and without the ε4a l l e l ew i t h
regards to gender, smoking habits, alcohol consumption,
exercise or use of a salty diet. Diabetes mellitus was less
prevalent in patients with the ε4 allele, but not reaching
statistical significance (20.5 vs. 26.5%, p = 0.286). No
differences were found regarding aspirine, angiotensin
receptor blockers, beta-blockers or calcium channel
antagonists usage among groups. Angiotensin-
converting enzyme inhibitors (ACEi) were used more
frequently in non-ε4 carriers; these patients also pre-
sented with higher blood pressure, although the average
values were in the normal range (135.6 ± 21.0 vs. 127.9
± 17.6 mmHg, p = 0.002). Regarding prior antidyslipi-
demic drug usage, including statins and fibrates, no sig-
nificant differences were found between ε4 carriers and
non-ε4 carriers.
However, regarding age at referral to the lipid clinic,
ε4-carriers were referred to hospital by their primary
care physicians at significant younger ages than non-ε4
carriers (44.2 ± 14.7 vs. 50.6 ± 13.8 years, p < 0.001).
We also separated mean age at referral by genotype
(Figure 1). The comparison of age at referral by the six
apoE genotypes showed a significant effect, with a sub-
stantially younger age of referral for homozygous E4/4
and for all genotypes with at least one copy of the ε4
allele (p < 0.001 for trend). Interestingly, at baseline, ε4-
carriers had similar lipid profiles compared with non-ε4
carriers, independently of the fraction analyzed (TC,
LDL, HDL, triglycerides, Lp(a), ApoA or ApoB). The
only significant difference found in lipid profile was in
apoE concentration with ε4-carriers having lower values
as expected (5.3 ± 3.0 vs. 7.3 ± 6.4 mg.dℓ
-1,p=0 . 0 0 8 ) .
Other biochemical variables, as creatinine or creatine
phosphokinase, as a marker of statin side effects, were
similar among groups and with average values within
the expected range.
Table 1 Frequency of apoE genotype and apoE allele by
gender
Total Male Female
N 463 272 192
Genotype
E2/2 11 (2.4%) 7 (2.6%) 4 (2.1%)
E3/2 42 (9.1%) 26 (9.6%) 16 (8.3%)
E4/2 8 (1.7%) 4 (1.5%) 4 (2.1%)
E3/3 298 (64.2%) 172 (63.2%) 126 (65.6%)
E4/3 93 (20.0%) 56 (20.6%) 37 (19.3%)
E4/4 11 (2.6%) 6 (2.2%) 5 (2.7%)
Allele
ε2 7.8% 8.1% 7.3%
ε3 78.9% 78.6% 79.4%
ε4 13.3% 13.3% 13.3%
Table 2 Baseline characteristics of the 455 patients with
different apoE alleles
Total Non-ε4
carriers
ε4 carriers p-
value
Age, years 49.2 ± 14.2 50.6 ± 13.8 44.2 ± 14.7
<0.001 Men [n (%)] 267 (58.7%) 156 (58.4%) 159
(59.6%) 0.826
BMI, kg.m
-2 28.1 ± 4.7 28.1 ± 4.8 28.1 ± 4.1 0.896
SBP, mmHg 133.8 ± 20.5 135.6 ± 21 127.9 ± 17.6 0.002
DBP, mmHg 83.5 ± 11.7 84.2 ± 11.5 80.9 ± 12.1 0.016
Heart rate, bpm 73.4 ± 12.3 73.5 ± 11.9 73.3 ± 13.8 0.915
TC, mg.dℓ
-1 275.9 ± 77.8 277.8 ± 81.3 269.4 ± 64.4 0.338
LDL, mg.dℓ
-1 157.7 ± 57.3 157.6 ± 58.5 158.0 ± 53.2 0.956
HDL, mg.dℓ
-1 49.6 ± 23.3 49.9 ± 24.9 48.6 ± 17.0 0.618
Triglycerides, mg.
dℓ
-1
210
(125-389)
218 (127-381) 177
(108-437)
0.535
1
Lp(a) (mg.dℓ
-1) 15 (6 - 37) 15 (6 - 37) 14 (6 - 36) 0.815
1
ApoE (mg.dℓ
-1) 6.8 ± 5.9 7.3 ± 6.4 5.3 ± 3.0 0.008
ApoB (mg.dℓ
-1) 143.3 ± 46.8 145.7 ± 49.3 135.5 ± 36.5 0.062
ApoA (mg.dℓ
-1) 152.4 ± 32.9 154 ± 32.4 146.8 ± 33.9 0.062
ApoB/ApoA 0.98 ± 0.36 1.0 ± 0.4 1.0 ± 0.3 0.593
Creatinine, mg.dℓ
-1 0.96 ± 0.49 1.0 ± 0.5 0.9 ± 0.3 0.495
CK (U.ℓ
-1) 117.1 ±
123.3
114.1 ± 83.9 127.3 ±
206.2
0.400
1 Comparisons for natural log-transformed variables. Values are median
(interquartile range). BMI: body mass index. SBP: systolic blood pressure; DBP:
diastolic blood pressure; TC: total cholesterol; LDL: low-density lipoprotein;
HDL: high density lipoprotein; Lp(a): lipoprotein (a); Apo: apolipoprotein; CK:
creatine kinase.
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All patients were followed in the specialized lipid clinic
for a median period of 3 years (interquartile range, 1 to
6). During this period, a strategy was implemented in
order to achieve the recommended ATP III goal levels
of cholesterol in all patients. The variation in lipid pro-
file is shown on Table 4. After the follow-up period,
57% of patients achieved a LDL value inferior to 130
mg.dℓ
-1 and 32% an LDL inferior to 100 mg.dℓ
-1.T h e
mean variation in TC was -18.2%, whereas HDL went
up 11.1% and triglycerides were reduced by -10.4% (all
p < 0.001 vs. baseline values). Significant differences
were found among ε4-carriers and non- ε4 carriers
regarding the effectiveness of the therapeutic interven-
tion. The proportion of patients reaching the LDL target
level was lower in the ε4-carriers and the absolute dif-
ference between TC at baseline and after therapeutic
intervention was 54.91 ± 67.0 mg.dℓ
-1 in the ε4 carriers,
compared with 78.8 ± 66.9 mg.dℓ
-1 in the ε4-non
carriers (p < 0.05). This correlates with an inferior rela-
tive reduction in TC within ε4-carriers than in ε4-non
carriers (-11.8 ± 2.3% vs. -19.9 ± 2.3%, p = 0.003). The
same was true for the other lipid subfractions, but with-
out reaching statistical significance (Figure 2).
Discussion
To our knowledge this is the first study to examine the
association between apoE genotypes and age at referral
to a specialized lipid clinic. We demonstrate that
patients carrying one or more copies of the ε4a l l e l ea r e
referred at significantly younger ages to the lipid clinic
and after a mean follow-up of three years these patients
have a poorer response to treatment.
We observed overall that the ε3a l l e l ew a st h em o s t
frequent, followed by the ε4a l l e l ea n dε2a l l e l e .T h i s
finding is ubiquitous for human populations [9]. In Eur-
ope, the frequency of apoE genotypes demonstrates a
North-South gradient, with a progressive decline in the
ε4 allele frequency from Northern (14-19%) to Southern
Table 3 Baseline prior history and medication of the 455 patients with different apoE alleles
Total Non-ε4 carriers ε4 carriers Odds-ratio (95% CI) p-value
Prior history
Diabetes mellitus 24.9% 26.3% 20.5% 0.723 (0.398-1.313) 0.285
Prior CHD 4.2% 4.9% 2.4% 0.478 (0.105 - 2.179) 0.330
Current smoker 21.2% 22.4% 17.1% 0.712 (0.375 - 1.353) 0.298
Alcohol consumption 52.8% 55.1% 45.1% 0.670 (0.408 - 1.101) 0.112
Regular exercise 10.6% 11.2% 8.4% 0.728 (0.308 - 1.720) 0.467
Use of a salty diet 57.3% 58.2% 54.2% 0.851 (0.519 - 1.395) 0.522
Prior medication
Aspirin 41.8% 44.5% 32.9% 0.612 (0.357 - 1.048) 0.072
Beta-blockers 22.0% 23.7% 16.7% 0.646 (0.325 - 1.284) 0.210
ACEi 33.3% 36.4% 23.0% 0.522 (0.287 - 0.950) 0.032
ARB 21.3% 21.9% 19.2% 0.817 (0.415 - 1.607) 0.614
Calcium antagonist 19.2% 19.9% 16.9% 0.817 (0.415 - 1.607) 0.557
Hypolipidemic drug* 81.6% 83.1% 76.5% 0.663 (0.344 - 1.277) 0.217
ACEi: angiotensin converting enzime inhibitor: ARB: angiotensin receptor blocker *Statin or fibrate.
Figure 1 Mean age at referral for the specialized lipid clinic, by
genotype. Bars are one standard error. P < 0.001 for trend.
Table 4 Follow-up lipid profile of patients
Total Non-ε4 carriers ε4 carriers p-value
LDL < 130
mg.dℓ
-1 (%)
57.2 61.4 43.2 0.002
LDL < 100
mg.dℓ
-1 (%)
32.4 34.9 23.9 0.052
TC variation (%) -18.2 ± 2.3 -19.9 ± 2.3 -11.8 ± 2.3 0.003
LDL variation (%) -16.0 ± 4.7 -17.9 ± 4.9 -9.5 ± 4.3 0.068
1
HDL variation (%) +11.1 ± 4.3 +11.7 ± 4.7 +7.1 ± 2.6 0.379
1
Triglyceride
variation (%)
-10.4 ± 8.5 -11.3 ± 8.7 -4.6 ± 7.8 0.508
1
1 Mann-Whintey test. TC: total cholesterol; LDL: low-density lipoprotein; HDL:
high density lipoprotein; TG: triglyceride.
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the ε4 allele was 13.3%, a value that is closer to the one
found in populations from Northern Europe and in
clear excess of the expected frequency of the ε4 allele in
the Portuguese healthy population (9.0%), one of the
lowest reported in Europe [7]. This disequilibrium
might be explained by the referred nature of our popu-
lation, although that fact is not obvious by the lipid con-
centrations, as there are no significant differences
among groups at baseline. Regarding the E2/2 genotype,
there is also a higher frequency (2.2%) than expected for
the Portuguese population (0.3%)[7], probably due to
the inclusion of some cases of hyperlipoproteinemia
type III[17].
ApoE ε4 allele has been linked to higher total and
LDL cholesterol plasma levels in several studies[7].
However, this was not the case in our population, where
we found no significant association between ε4-carrier
status and baseline TC and LDL. The associations
between the apoE polymorphism and plasma concentra-
tions of HDL, apoA, Lp(a) and triglycerides have been
more inconsistent in the literature, with results that
range from no association[18,19] to associations that
vary by sex [20]. We found no association between
those lipid traits and ε4-carrier status in our population.
We also found, as expected, that ε4-carriers had lower
plasma concentrations of apoE, compared with ε4-non
carriers. It has been suggested that high apoE plasma
levels have prognostic impact, independent of apoE gen-
otypes, lipid values and other cardiovascular risk factors
[7,21]. Further research is needed to clarify to role of
apoE concentration in the assessment of global cardio-
vascular risk.
As reported by Chiodoni et al.[22], we found a non-
significant trend of a lower prevalence of diabetic
patients in ε4-carriers compared with the non-ε4c a r -
riers, this disease being highly prevalent in our cohort
(21.1%). This can be due to the younger age of presenta-
tion of the ε4-carriers or to a distinctive effect of the ε4
allele on carbohydrate metabolism that remains to be
elucidated.
Although no differences were found in lipid profiles
among ε4-carriers and non-carriers, the former were
consistently referred at younger ages to the lipid clinic,
with a clear and significant gradient to patients with
more copies of the ε4 allele being referred at propor-
tionally younger ages. What alerted the primary care
physicians to refer such patients at younger ages?
Several reports studied the interaction between age,
apoE and target organ disease. Newman et al. demon-
strates a significant trend for early coronary revasculari-
zation surgery for patients with higher number of copies
of the ε4 allele, compared with ε3a n dε2 carriers[12].
Other studies have also indicated a substantial (16-fold)
increase in the prevalence of the ε4a l l e l ei np a t i e n t s
referred for coronary angioplasty[23] and its predictive
power regarding coronary vessel restenosis [24]. In our
population, although not having a higher incidence of
prior CHD, ε4-carriers could have presented with more
intense abnormalities in lipid profile than expected at
younger ages to their primary care physicians, prompt-
ing the referral to the hospital.
Other factor that may have been implicated in early
referral was the level of response to lipid-lowering
therapy. During follow-up, the TC of our patients was
lowered in average 18%, the LDL-C 16% and TG 10%
and HDL was improved on average 11%. These results
compare with those from the GISSI-Prevenzione (GISSI-
P) study, also conducted in a Southern European popu-
lation and that obtained at a mean follow-up time of 24
months similar reductions in the lipid profile with the
use of pravastatin (20 to 40 mg) [25]. We report a lower
v a r i a t i o ni nT Ci nε4-carriers compared to non-ε4c a r -
riers, with both groups under a similar hypolipidemic
strategy (-19.9 ± 2.3 vs. -11.8 ± 2.3%, p = 0.003). In fact,
although departing from slightly lower TC levels, ε4-
carriers reached the end the follow-up period with
higher TC levels than non-ε4 carriers and with a higher
proportion of patients with LDL over 130 mg.dℓ
-1.
The effect of the apoE genotype on antidyslipidemic
drugs’ efficacy, namely statins, has been thoroughly stu-
died in the last years[26]. Although several efforts have
been made to identify genes that might be involved in
statin response, a recent analysis for the Treating to
New Targets (TNT) study concluded that, after analyz-
ing almost 300,000 putative sites, only polymorphisms
in the apoE gene were found to influence statin
Figure 2 Three-year follow-up variation in lipid levels, by ε4-
carrier status. TC: total cholesterol; LDL: low-density lipoprotein;
HDL: high density lipoprotein; TG: triglyceride; var: variation.
* P < 0.05.
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this gene on lipid metabolism. In this genome-wide
study, patients with apoE 4/4 allele had a lower response
to atorvastatin treatment than patients with E3/3 allele
regarding LDL levels (37.7 vs. 40.3%) [27]. Taken
together, the majority of studies indicate that patients
with the ε4 allele seem to have the poorest and those
with the ε2 allele the strongest response to statins
regarding LDL lowering [28-31]; in addition, ε2 carriers
may reach the LDL treatment goals more frequently
than ε4 carriers [32]. These findings have not been
reproduced by other authors [33-35]. In a subanalysis of
the GISSI-P study, only carriers of the considered high-
risk ε4 allele seemed to benefit from the treatment with
statin, regarding mortality [22], corroborating the find-
ings of the 4S subanalysis, where the treatment with
simvastatin neutralized the higher risk of mortality of ε4
carriers[33]. This fact should alert physicians to aggres-
sively treat to target lipid goals in these patients.
Our population was selected by primary care physi-
cians for follow-up at a specialized lipid clinic and does
not represent a cross-section of the population as a
whole; however, based on cardiovascular risk factors,
our population reflects the usual adult population seen
in a primary care setting. The reported disequilibrium in
genotype frequencies compared to those expected in a
non-selected healthy population reflects the referral nat-
ure of our population. Numerous factors may have
guided the decision to refer to lipid clinic and we can
only speculate on what those factors may be. However,
the fact remains that in the population studied, there
was a distinct association between the presence of the
apoE ε4 allele and an earlier presentation for tertiary
specialized lipid care. We also demonstrate that after a
mean follow-up of three years, the impact of therapeu-
tics in the level of TC was significantly lower in ε4-car-
riers. One may hypothesize that, although having similar
lipid levels at baseline compared with non-ε4 carriers,
t h ec o m b i n a t i o no fam o r es e v e r el i p i dp r o f i l ea t
younger ages with a poorer response to an already
initiated standard hypolipidemic therapy may all had a
role in the decision of the primary care physician to
refer these patients. We must highlight that primary
care physicians were blinded to apoE genotypes, as gen-
otyping was performed only at the hospital.
The study has some limitations. The inclusion of par-
ticipants receiving medication for CHD, diabetes, hyper-
tension or hypercholesterolemia can alter physiologic
lipid levels and confound the lipid associations. How-
ever, no differences were found regarding the frequency
of usage of these medications in primary care between
groups, except for ACEi. Moreover, as the primary care
physicians were not aware of the genotypes, the referral
was made in an entirely blinded fashion. The inexistence
of a defined protocol for statin use during follow-up
time in the specialized lipid consultation is compensated
by the fact that no differences were found on lipid-low-
ering therapies management on both groups.
Conclusions
In conclusion, we have demonstrated that the presence
of the apoE ε4 allele is associated with referral at
younger ages to a specialized lipid clinic, although no
differences were found regarding baseline lipid profile
that could account for such earlier referrals. Moreover,
these patients had a poorer response to the antidyslipi-
demic treatment instituted during the follow up period.
Intensive therapeutical strategies must be followed to
achieve the recommended target goals of lipid levels,
particularly in high-risk patients as ε4-carriers. Our find-
ings suggest that pharmacogenomics could be consid-
ered for individualized tailoring of global cardiovascular
risk assessment strategies.
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